<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Prescription drug misuse: Epidemiology, prevention, identification, and management
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Prescription drug misuse: Epidemiology, prevention, identification, and management
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Prescription drug misuse: Epidemiology, prevention, identification, and management
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William C Becker, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Joanna L Starrels, MD, MS
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew J Saxon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Friedman, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Jul 26, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H29429846">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Opioid analgesics, benzodiazepines, other sedatives and tranquilizers, and stimulants have important medical uses, but they also stimulate the reward center of the brain. In susceptible individuals, this can lead to misuse, substance use disorders, and other serious consequences. It has also led to the development and persistence of an illicit market for these medications, which creates additional public health risk due to mislabeled, contaminated, or counterfeit products.
        </p>
        <p>
         Despite government regulation of these medications, prescription drug misuse and its consequences persist. Clinicians who prescribe these medications have an important role in preventing, identifying, and managing problems related to prescription drug misuse.
        </p>
        <p>
         This topic reviews the epidemiology, prevention, identification, and management of prescription drug misuse. The epidemiology, pathogenesis, clinical manifestations, course, assessment, diagnosis, and treatment of opioid use disorder, benzodiazepine use disorder, and stimulant use disorder are discussed separately.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">
          "Benzodiazepine use disorder"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14839.html" rel="external">
          "Methamphetamine use disorder: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">
          "Cocaine use disorder: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/16750.html" rel="external">
          "Stimulant use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/106878.html" rel="external">
          "Stimulant use disorder: Treatment overview"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29429852">
         <span class="h1">
          TERMINOLOGY
         </span>
        </p>
        <p class="headingAnchor" id="H341972383">
         <span class="h2">
          Controlled substances
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to their potential for misuse, addiction, and illicit diversion, opioid analgesics, stimulants, and benzodiazepines and other sedatives/hypnotics are regulated, restricting whether and how they can be prescribed. In the United States, these drugs are referred to as "controlled substances" and subject to federal regulations  (
         <a class="graphic graphic_table graphicRef66064" href="/z/d/graphic/66064.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H341971835">
         <span class="h2">
          Prescription drug misuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Any use of a prescription medication that is outside of the manner and intent for which it was prescribed. This includes overuse, use to get high, diversion (sharing or selling to others), nonprescribed use or nonclinician sources of the medication, having nondisclosed prescribers, and concurrent use of alcohol, illicit substances, or nonprescribed controlled medications. While commonly present in cases of substance use disorder, misuse is not sufficient for diagnosis of a substance use disorder.
        </p>
        <p class="headingAnchor" id="H341971845">
         <span class="h2">
          Nonmedical use
         </span>
         <span class="headingEndMark">
          —
         </span>
         Initially defined by the National Survey on Drug Use and Health (NSDUH), as use of a medication that was not prescribed to the individual, or use "only for the feeling or experience it caused” [
         <a href="#rid1">
          1
         </a>
         ]. The NSDUH has eliminated the term in favor of “misuse,” which the survey defines as use in any way not directed by a clinician, including use without a prescription of one’s own; use in greater amounts, more often, or longer than told to take a drug; or use in any other way not directed by a clinician.
        </p>
        <p class="headingAnchor" id="H341971859">
         <span class="h2">
          Prescription drug use disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         Misuse of a prescription drug meeting the American Psychiatric Association’s Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) criteria as a substance use disorder, which can be specified as mild, moderate, or severe [
         <a href="#rid2">
          2
         </a>
         ]. Substance use disorder replaced the terms substance abuse and substance dependence from the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Prescription drug use disorders can also be characterized by the type of prescription drug used. (See
         <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">
          "Benzodiazepine use disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29429858">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Misuse of prescription drugs has generally increased concurrently with greater prescribing of medication for therapeutic use, with some declines in misuse as prescribing rates have fallen. This is particularly true of opioid analgesics prescribed for patients with chronic pain, stimulants prescribed for individuals with attention deficit hyperactivity disorder (ADHD), and benzodiazepines prescribed for anxiety/insomnia; prescribing for each increased markedly between 2000 and 2010 [
         <a href="#rid3">
          3-5
         </a>
         ]. After decades of increasing prescription opioid use, data since the mid-2010s indicated a decline in opioid prescribing [
         <a href="#rid6">
          6
         </a>
         ] and in nonmedical opioid use by adolescents [
         <a href="#rid7">
          7
         </a>
         ]. With decreasing opioid prescribing, more commercially insured adults in the United States were prescribed depressants such as benzodiazepines and “z drugs” than were prescribed opioids from 2014 to 2019 [
         <a href="#rid8">
          8
         </a>
         ].Prescription opioid use disorder has been reported to affect 1.8 percent of individuals 12 and over, more than twice as many as were affected by prescription tranquilizer or sedative use disorder (0.8 percent), and more than three times as many affected by prescription stimulant use disorder (0.5 percent) [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29429864">
         <span class="h2">
          Opioid analgesics
         </span>
        </p>
        <p class="headingAnchor" id="H29429872">
         <span class="h3">
          Misuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Estimates of the prevalence of opioid misuse among patients who are prescribed opioid analgesics vary widely, from 12 to 78 percent [
         <a href="#rid10">
          10-17
         </a>
         ], reflecting differences in the sample populations and definitions of opioid misuse among studies.
        </p>
        <p>
         As an example, the National Survey on Drug Use and Health (NSDUH) in the United States estimated that among approximately 76 million United States adults prescribed opioid drugs in the prior year, 12 percent reported prescription opioid misuse [
         <a href="#rid17">
          17
         </a>
         ]. Compared with individuals who used prescribed opioids and did not report misuse, those reporting misuse of prescription opioids reported higher rates of other substance use, including cannabis, heroin, and benzodiazepine use, and were more likely to be depressed.
        </p>
        <p>
         As opioid prescribing has decreased over the last several years, so have rates of misuse, particularly in certain age groups. A study analyzing NSDUH survey years 2015 to 2019 found significant declines in past‐year opioid misuse in adolescents, young adults, and adults 26 to 34 years and a nonsignificant decline among adults 35 to 64 years, with a nonsignificant increase in those 65 and older [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p>
         Motives for prescription opioid misuse tend to differ by age group. Among 5800 individuals with prescription opioid misuse who participated in the 2015 to 2016 NSDUH, a greater proportion of adults 50 years or older misused opioids solely for the purpose of pain relief compared with young adults age 18 to 25 (65 versus 35 percent) [
         <a href="#rid19">
          19
         </a>
         ]. Other motives for prescription opioid misuse included for relaxation, experimentation, and sleep. Prescription opioid misuse for motives other than pain relief was associated with greater odds of benzodiazepine misuse, substance use disorder, and suicidal ideation in the prior year.
        </p>
        <p>
         A National Institute on Drug Abuse-funded survey of over 45,000 public and private high school students found a marked decline in past-year misuse of prescription opioids among high school seniors over the previous six years: from 8.7 to 4.2 percent [
         <a href="#rid20">
          20
         </a>
         ].
        </p>
        <p>
         Another study reported an association between nonmedical prescription opioid misuse and subsequent initiation of heroin use in adolescents [
         <a href="#rid21">
          21
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29429886">
         <span class="h3">
          Use disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         In a systematic review, the incidence of opioid use disorder among patients prescribed opioids for chronic pain was estimated to be 8 to 12 percent [
         <a href="#rid22">
          22
         </a>
         ]. Cross-sectional studies from 2008 to 2015 reported the prevalence of opioid use disorder among patients prescribed long-term opioids for chronic pain to range from 3 to 26 percent [
         <a href="#rid10">
          10,23,24
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         26 percent of patients within a large United States health system who were prescribed long-term opioids met criteria for DSM-IV opioid dependence in the past year [
         <a href="#rid23">
          23
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         19.7 percent of primary care patients prescribed long-term opioids met criteria specifically for prescription drug misuse or dependence in the past year [
         <a href="#rid24">
          24
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         3 percent of primary care patients prescribed long-term opioids met criteria for current opioid dependence using a more conservative 30-day measure [
         <a href="#rid10">
          10
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         The prevalence of opioid use disorder involving prescription opioids among the United States general population rose markedly from the mid-1990s to the mid-2010s and has since decreased. The proportion of United States individuals seeking substance use disorder treatment who reported prescription opioids as the primary substance used increased from 1.0 to 9.3 percent between 1995 and 2013 [
         <a href="#rid25">
          25
         </a>
         ]; 88 percent of these individuals were White [
         <a href="#rid25">
          25,26
         </a>
         ]. From 1995 to 2010, individuals in rural counties were more likely than those in urban counties to report prescription opioids as the primary substance (10.6 versus 4.0 percent) [
         <a href="#rid27">
          27
         </a>
         ]. In 2019, 6.8 percent of United States individuals seeking substance use disorder treatment reported prescription opioids as the primary substance [
         <a href="#rid28">
          28
         </a>
         ], compared with 23.4 percent for heroin.
        </p>
        <p class="headingAnchor" id="H29429895">
         <span class="h3">
          Morbidity and mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Concurrent with increased use of opioid analgesics for pain management from the 1990s to the mid-2010s, associated morbidity and mortality rose markedly. In a national survey, from among 63,600 deaths in the United States in a single year, approximately 42,000 (66 percent) involved opioids [
         <a href="#rid29">
          29
         </a>
         ]. However, while opioid prescribing has decreased, opioid-related overdose deaths have continued to rise, with approximately 68,000 in 2020 [
         <a href="#rid30">
          30
         </a>
         ]. Of overdose deaths involving opioids, approximately 30 percent additionally involved benzodiazepines [
         <a href="#rid31">
          31
         </a>
         ], which compound the sedating and respiratory-depression effects of opioids and increase overdose risk. The majority of decedents from drug overdose were males between 1999 and 2014; however, overdose deaths involving opioid analgesics increased 516 percent among females and 300 percent among males [
         <a href="#rid32">
          32
         </a>
         ]. The pathway from prescription opioid use disorder to heroin has been increasingly recognized [
         <a href="#rid33">
          33
         </a>
         ], and the Centers for Disease Control and Prevention identified three waves of the overdose epidemic: prescription opioids, heroin, and most recently, ultra-potent illegally manufactured
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         [
         <a href="#rid29">
          29
         </a>
         ]. The epidemiology of opioid overdose and prevention of lethal opioid overdose is discussed in greater detail separately. (See
         <a class="medical medical_review" href="/z/d/html/99945.html" rel="external">
          "Prevention of lethal opioid overdose in the community"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29429902">
         <span class="h3">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patient factors that have been associated with increased risk for opioid analgesic misuse when prescribed the medication for chronic pain include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Substance use disorder, including tobacco or alcohol use disorder, is consistently identified as a risk factor [
         <a href="#rid11">
          11-13,24,34,35
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Family history of a substance use disorder [
         <a href="#rid24">
          24,36
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mental health disorder, including depression, posttraumatic stress disorder, and anxiety disorders [
         <a href="#rid10">
          10,23,24,34,36-38
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of legal problems or incarceration [
         <a href="#rid16">
          16,17,24
         </a>
         ]
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Age less than 40 to 45 years old, in most studies [
         <a href="#rid10">
          10,11,16,34,39
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Studies are most robust for misuse, but the risk factors noted above are also generally considered to be risk factors for developing opioid use disorder and for overdose. (See
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment", section on 'Risk factors'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29429909">
         <span class="h2">
          Stimulants
         </span>
        </p>
        <p class="headingAnchor" id="H29429917">
         <span class="h3">
          Misuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Stimulant prescribing for ADHD has increased since the 1990s [
         <a href="#rid3">
          3,8
         </a>
         ].
         <strong>
         </strong>
         Focusing on pharmaceutical stimulants only, data from the NSDUH has found that the general population past-year prevalence of prescription stimulant use (eg,
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         or amphetamine products) was 6.4 percent and prevalence of misuse was 2.1 percent in the United States [
         <a href="#rid40">
          40,41
         </a>
         ]. Prevalence of prescription stimulant misuse was highest among 18- to 25-year-olds. Several studies have focused exclusively on younger populations; the reported prevalence of past-year pharmaceutical stimulant misuse was 5 to 9 percent [
         <a href="#rid42">
          42
         </a>
         ], and past-year methylphenidate use was 2 to 5 percent [
         <a href="#rid43">
          43
         </a>
         ] among high school students. For college students, studies reported past-year pharmaceutical stimulant misuse prevalence rates of 5 to 6 percent, and lifetime prevalence rates of 5 to 43 percent [
         <a href="#rid40">
          40
         </a>
         ]. Another study analyzing NSDUH survey years 2015 to 2019 found significant annual declines in prescription stimulant misuse in young adults but slightly increasing annual rates among adults 35 to 49 years. In all other age groups, annualized changes in past‐year stimulant misuse were nonsignificant [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29429924">
         <span class="h3">
          Use disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to the NSDUH, among individuals 12 or older who sought substance use treatment in the past year, 3.4 percent were for stimulant use disorder [
         <a href="#rid41">
          41
         </a>
         ]. Another study reported that approximately 0.5 percent of United States individuals 12 or older had a past-year prescription stimulant use disorder [
         <a href="#rid9">
          9
         </a>
         ]. However, robust estimates of the prevalence of pharmaceutical stimulant use disorders are lacking.
        </p>
        <p class="headingAnchor" id="H29429931">
         <span class="h3">
          Morbidity and mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         In 2019, over 16,000 individuals in the United States died of overdose death involving psychostimulants (methamphetamine, amphetamine, and
         <a class="drug drug_general" data-topicid="9638" href="/z/d/drug information/9638.html" rel="external">
          methylphenidate
         </a>
         ). This corresponds to a more than six-fold increase in the age-adjusted rate of overdose from 2012 to 2019 [
         <a href="#rid44">
          44
         </a>
         ]. The number of emergency department visits involving psychostimulants increased similarly from 2.2 per 10,000 residents to 12.9 per 10,000 residents, from 2008 to 2018 [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
         Stimulants may:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increase blood pressure
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increase heart rate
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Increase body temperature
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decrease sleep
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Decrease appetite
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cause agitation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cause anxiety
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cause paranoia
        </p>
        <p>
        </p>
        <p>
         These symptoms are all more likely to occur when higher-than-prescribed doses are taken.
        </p>
        <p>
         The overdose toxidrome may include [
         <a href="#rid46">
          46
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mydriasis
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Tremor
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Agitation
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hyperreflexia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Combative behavior
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Confusion
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hallucinations
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Delirium
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Anxiety
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Paranoia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Seizures
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Movement disorders
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29429938">
         <span class="h3">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         Studies of risk factors for pharmaceutical stimulant misuse have been predominantly among youths and young adults ages 12 to 25, especially college students. Reported risk factors for stimulant misuse include [
         <a href="#rid40">
          40,47
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         White race
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Involvement in a fraternity or sorority
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Grade point average below 3.5
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         At least one episode of binge drinking in the past two weeks
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Past-month cannabis use
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Presence of conduct disorder
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29429944">
         <span class="h2">
          Sedatives-hypnotics
         </span>
        </p>
        <p class="headingAnchor" id="H29429951">
         <span class="h3">
          Misuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Surveys of a nationally representative sample of United States residents age 12 and older found
         <strong>
         </strong>
         a fairly stable prevalence of past-month nonmedical use of sedatives (0.1 to 0.2 percent of respondents) and tranquilizers (0.7 to 0.9 percent of respondents) from 2002 to 2014 [
         <a href="#rid48">
          48
         </a>
         ]. In another survey, the prevalence of past-year tranquilizer misuse among United States residents age 12 and older was 2.3 percent [
         <a href="#rid49">
          49
         </a>
         ]. Benzodiazepine misuse accounted for the vast majority (89 percent) of tranquilizer misuse, and
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         products were the most commonly misused benzodiazepines. A study analyzing NSDUH survey years 2015 to 2019 found significant annual declines in benzodiazepine misuse in young adults but slightly increasing annual rates among adults 35 to 49 years. In all other age groups, changes in past‐year benzodiazepine misuse were nonsignificant [
         <a href="#rid18">
          18
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29429958">
         <span class="h3">
          Use disorder
         </span>
         <span class="headingEndMark">
          —
         </span>
         According to a national drug survey, estimated past-year prescription sedative or tranquilizer use disorder in the United States affected 682,000 individuals, or 0.2 percent of people age 12 or older. While this has been fairly stable since 2015 [
         <a href="#rid50">
          50
         </a>
         ], combined opioid use disorder and benzodiazepine use disorder increased dramatically in the past twenty years; an analysis of substance use disorder treatment admissions showed a 569.7 percent increase in treatment admissions with both benzodiazepine and prescription opioid use from 2000 to 2010 [
         <a href="#rid51">
          51
         </a>
         ]. Specific substance use disorders are described separately. (See
         <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">
          "Benzodiazepine use disorder"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7804.html" rel="external">
          "Opioid use disorder: Epidemiology, clinical features, health consequences, screening, and assessment"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29429964">
         <span class="h3">
          Morbidity and mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sedatives and tranquilizers have potent, dose-dependent central nervous system depressant effects. In the United States, overdose death involving benzodiazepines increased more than fourfold from 2002 to 2015 [
         <a href="#rid32">
          32
         </a>
         ]. Co-ingestion of sedatives and tranquilizers with alcohol or opioids is an increasingly recognized and prevalent cause of overdose death [
         <a href="#rid5">
          5,52-54
         </a>
         ]. From 2002 to 2015, there was a fivefold increase in overdose deaths involving both benzodiazepines and opioids [
         <a href="#rid32">
          32
         </a>
         ]. In a multistate study of benzodiazepine-involved overdose deaths, 92.7 percent also involved an opioid, and the majority involved
         <a class="drug drug_general" data-topicid="8441" href="/z/d/drug information/8441.html" rel="external">
          fentanyl
         </a>
         [
         <a href="#rid55">
          55
         </a>
         ]. Importantly, products sold illicitly as benzodiazepine medications such as
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         have been found to contain synthetic opioids such as fentanyl, increasing their overdose risk.
        </p>
        <p class="headingAnchor" id="H29429970">
         <span class="h3">
          Risk factors
         </span>
         <span class="headingEndMark">
          —
         </span>
         A study of three years of United States survey data identified risk factors for past year nonmedical use of sedatives or tranquilizers [
         <a href="#rid56">
          56
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         White race
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Female sex
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Uninsured
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unemployed
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Panic symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other psychiatric symptoms
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Alcohol use disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Cigarette use
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Illicit drug use
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         History of IV drug use
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29429976">
         <span class="h1">
          PREVENTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Principal strategies for clinicians to prevent prescription drug misuse and its consequences are optimizing alternative treatments, including avoiding prescribing controlled substances in situations where alternative treatments are likely to be safe and effective; conducting ongoing assessment of risk for each patient; establishing a treatment plan that includes clear communication with the patient; and limiting dose to the lowest effective dose.
        </p>
        <p class="headingAnchor" id="H29429982">
         <span class="h2">
          Optimize alternative treatments
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first principle in prevention is to avoid prescribing controlled substances when safer alternatives are available and are likely to be effective. Clinical indications for prescribing controlled substances, such as pain, anxiety, and attention deficit hyperactivity disorder, each have evidenced-based treatment modalities that can replace or complement use of controlled substances. These include nonpharmacologic treatment with self-management strategies, behavioral treatments, physical therapy, as well as noncontrolled pharmacotherapy. (See
         <a class="local">
          'Controlled substances'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/126111.html" rel="external">
          "Approach to the management of chronic non-cancer pain in adults"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118534.html" rel="external">
          "Attention deficit hyperactivity disorder in adults: Treatment overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/101879.html" rel="external">
          "Generalized anxiety disorder in adults: Management"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29429994">
         <span class="h2">
          Patient risk assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Consensus-based guidelines recommend that clinicians initiate or chose to continue controlled substances only in patients for whom the likely benefits will outweigh the risks [
         <a href="#rid57">
          57,58
         </a>
         ]. Contraindications to treatment with controlled substances include [
         <a href="#rid57">
          57
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Current untreated substance use disorder
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Poorly controlled psychiatric illness
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Inconsistent follow-up
        </p>
        <p>
        </p>
        <p>
         There are scant data on predicting likelihood of benefit and harm in controlled substance prescribing. Tools have been developed to help predict risk of developing misuse [
         <a href="#rid59">
          59-61
         </a>
         ], but none have been shown to impact outcomes, and few have been validated in primary care, where most controlled substances are prescribed.
        </p>
        <p>
         To assess risk for prescription drug misuse, it is generally necessary to collect both patient-reported data and collateral data from other providers and objective sources. Patient-reported data include a thorough substance use history, mental health history, family and social history, as well as physical examination to assess for signs of substance use (eg, track marks and stigmata of chronic liver disease). It is also helpful to review medical records, speak with previous or current providers, check the state prescription monitoring program, and conduct drug testing. (See
         <a class="local">
          'Urine drug testing'
         </a>
         below.)
        </p>
        <p>
         The risk assessment should help to inform decisions about whether to prescribe controlled substances, and, if the clinician chooses to prescribe them, will help to inform the intensity of monitoring and determine which adjuvant treatments (eg, behavioral health) are indicated.
        </p>
        <p class="headingAnchor" id="H29429988">
         <span class="h2">
          Establishing a treatment plan
         </span>
         <span class="headingEndMark">
          —
         </span>
         We discuss the potential risks, benefits, and treatment alternatives with a patient before starting a controlled substance [
         <a href="#rid58">
          58
         </a>
         ]. We also discuss the strategies that will be used to monitor for and respond to risks of potential misuse that arise in the course of treatment, including defining conditions in which a safe discontinuation of controlled substances and/or transition to substance use disorder treatment would be indicated. Clear communication is critical; patients need to know what is and is not considered safe use of controlled substances. We recommend this be done in a nonjudgmental, nonstigmatizing way that promotes patients’ understanding and comfort in asking questions.
        </p>
        <p>
         Written documents such as informed consents, agreements on terms of treatment, or treatment plans can be useful to document this information/agreement between patients and prescribers. Though evidence for a treatment agreement's effectiveness in reducing misuse of controlled substances is not robust [
         <a href="#rid62">
          62
         </a>
         ], most experts promote its role in documenting shared decision-making, treatment goal-setting, informed consent, and defining the monitoring plan [
         <a href="#rid57">
          57
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29430000">
         <span class="h2">
          Limiting exposure
         </span>
         <span class="headingEndMark">
          —
         </span>
         Limiting exposure to controlled substances can help prevent prescription drug misuse. This includes choosing alternate treatments when possible and when controlled substances are prescribed, limiting the dose, duration, or number of prescriptions. The most rigorous data to support these strategies are for opioid prescribing. Greater daily opioid doses and greater numbers of prescriptions per month are associated with a higher risk of overdose death [
         <a href="#rid63">
          63-65
         </a>
         ]. Based on these findings, the Centers for Disease Control and Prevention [
         <a href="#rid58">
          58
         </a>
         ] recommended in its Guideline for Prescribing Opioids for Chronic Pain that clinicians avoid increasing the dose of prescribed opioids for chronic pain beyond 90
         <a class="drug drug_general" data-topicid="9788" href="/z/d/drug information/9788.html" rel="external">
          morphine
         </a>
         milligram equivalents per day. Of note, the updated guideline removed mention of specific dose thresholds but still strongly recommends limiting to the lowest effective dose [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         It is important to frequently perform detailed medication reconciliation to understand how patients actually take controlled substances, rather than relying exclusively on close-ended questions like, “Do you take your medication as prescribed?” Prescribing quantities of controlled substances that exceed what the patient consumes can contribute to hoarding of medication and increase the risk of diversion and misuse.
        </p>
        <p>
         As above, each patient’s daily dose should be limited to the lowest effective dose for the individual patient. When a patient’s symptoms are controlled, it is prudent in many cases to offer and attempt dose reductions as tolerated to minimize exposure and risk. Given evidence of harms of rapid tapering or discontinuation including opioid withdrawal and suicidality, it is important to make tapering decisions in a collaborative and tolerable way [
         <a href="#rid66">
          66-73
         </a>
         ]. The 2022 guideline from the Centers for Disease Control and Prevention includes guidance on patient-centered prescription opioid tapering [
         <a href="#rid74">
          74
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H29430006">
         <span class="h1">
          IDENTIFICATION AND MANAGEMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         Clinicians have a clinical responsibility to monitor patients to whom they prescribe controlled substances on an ongoing basis for misuse of these medications [
         <a href="#rid57">
          57,58,75
         </a>
         ]. Practitioners should adhere to policies of their state boards in the United States, and medical regulatory authorities in other countries, which may include specific actions not discussed here. Experts recommend a "universal precautions" [
         <a href="#rid76">
          76
         </a>
         ] approach incorporating a standard prescribing and monitoring framework for all patients prescribed the medications that includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Establishing a clear clinician-patient relationship, as with any patient.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Documenting in the patient’s medical record [
         <a href="#rid57">
          57,77
         </a>
         ]:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A medical history, including substance use and mental health
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Physical examination
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Medical decision-making, including assessment of benefit and harm
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Plan of care
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Regular follow-up with standardized monitoring for benefit and harm. (See
         <a class="local">
          'Regular follow-up'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Drug testing. (See
         <a class="local">
          'Urine drug testing'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Use of prescription monitoring programs where available. (See
         <a class="local">
          'Prescription monitoring programs'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discussing all planned monitoring strategies in a treatment agreement. (See
         <a class="local">
          'Establishing a treatment plan'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H29430012">
         <span class="h2">
          Regular follow-up
         </span>
         <span class="headingEndMark">
          —
         </span>
         Frequent in-person follow-up with patients on controlled substances is preferred; however, if not feasible (eg, due to distance or frailty), video-based visits may be acceptable. During follow-up visits, we monitor for and document benefits and harms of treatment, including concerning behaviors that may indicate misuse or a use disorder. Guidelines vary, but visits should generally occur at least every three months and more frequently in higher risk circumstances, such as during periods of dose adjustment [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         For follow-up assessment of risks and benefits in patients who are prescribed opioids for chronic pain, the "Five A's" provides a useful framework:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Analgesia
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Activities of daily living (ie, assessment of functional status)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Addiction
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adverse effects
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Adherence to the treatment plan
        </p>
        <p>
        </p>
        <p>
         Physical examination is essential and can provide evidence of intoxication, oversedation, withdrawal, or findings indicative of drug injection or intranasal use. Involving a patient's family member or friend can be useful for obtaining collateral history about a patient's functioning and use of the medications.
        </p>
        <p class="headingAnchor" id="H29430018">
         <span class="h2">
          Urine drug testing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Urine drug testing provides objective data to confirm that patients have taken the prescribed medication and to help identify use of nonprescribed substances that could interfere with the safety or effectiveness of treatment [
         <a href="#rid57">
          57
         </a>
         ]. Random drug testing, as opposed to scheduled testing, may be more likely to detect undisclosed drug use. While evidence that routine urine drug testing decreases controlled substance misuse is lacking [
         <a href="#rid62">
          62
         </a>
         ], urine drug testing is effective at identifying illicit and nonprescribed drug use [
         <a href="#rid78">
          78-81
         </a>
         ]; it has been shown to be better than clinician assessment alone [
         <a href="#rid10">
          10,79,82
         </a>
         ]. As an example, among patients whose clinicians believed were not at risk for medication misuse, 60 percent had urine drug tests showing the presence of an illicit drug or the absence of a prescribed medication [
         <a href="#rid83">
          83
         </a>
         ].
        </p>
        <p>
         Urine is the most commonly tested bodily fluid for drugs in clinical care because the window of detection is longer than for blood and because oral fluid testing is susceptible to false negatives, particularly in smokers. Clinicians must be aware of the limitations (eg, false-positive and false-negative results) of the drug test assays that they use. Misinterpretation of results is common and could negatively affect patient care [
         <a href="#rid84">
          84-86
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/13846.html" rel="external">
          "Testing for drugs of abuse (DOAs)"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/118689.html" rel="external">
          "Urine drug testing for patients with chronic pain"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H29430024">
         <span class="h2">
          Prescription monitoring programs
         </span>
         <span class="headingEndMark">
          —
         </span>
         Prescription monitoring programs (PMP) provide an online database listing all prescriptions of controlled substances dispensed for each patient by pharmacies in the covered region. All states in the United States have operational PMPs; other countries have similar programs. Where possible, and in accordance with state policies, prescribers should query the PMP before prescribing controlled substances to a patient, to check for undisclosed prescriptions for controlled substances. Receiving undisclosed controlled substances from other prescribers is a type of prescription drug misuse, could indicate substance use disorder or diversion, and elevates the risk for drug-drug interactions and overdose. Reviewing PMP data also helps the clinician determine when prescriptions were filled, to more accurately assess expected end date and avoid unintentional early refills.
        </p>
        <p>
         Clinicians making use of PMP data should be aware that PMP databases may not include all medical sources. As an example, PMP data in the United States usually does not include information on
         <a class="drug drug_general" data-topicid="9623" href="/z/d/drug information/9623.html" rel="external">
          methadone
         </a>
         dispensed for the treatment of opioid use disorder from opioid treatment programs. Access to dispensing data from neighboring states is variable and increasing. Occasionally, reporting errors from pharmacies occur, and calling a pharmacy directly may be necessary to confirm an unexpected finding in the PMP.
        </p>
        <p class="headingAnchor" id="H1768501266">
         <span class="h2">
          Clinician education
         </span>
         <span class="headingEndMark">
          —
         </span>
         An epidemic of lethal opioid overdoses in the United States has prompted numerous initiatives to educate clinicians about appropriate opioid use and influencing their prescribing practices [
         <a href="#rid74">
          74,87,88
         </a>
         ]. As an example, practice guidelines have been disseminated by a variety of organizations targeting various clinician populations and clinical settings, in some cases with follow-up measurement of their impact.
        </p>
        <p>
         As an example, dissemination of a practice guideline aimed at reducing inappropriate opioid prescribing by emergency clinicians in Ohio was associated with a 12 percent reduction (95% CI 17.7 to -6.3) in prescriptions per month statewide [
         <a href="#rid89">
          89
         </a>
         ]. The guideline encouraged emergency clinicians, when considering an opioid prescription, to review the patient’s recent prescription history in the state’s prescription drug monitoring database; limit the quantity provided; refer the patient for further evaluation, treatment, and monitoring; and provide education about opioid risks and limited benefits. (See
         <a class="local">
          'Prescription monitoring programs'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H29430036">
         <span class="h2">
          Addressing misuse
         </span>
         <span class="headingEndMark">
          —
         </span>
         Before starting treatment with a controlled substance, providers should have a well thought-out plan for how to respond to evidence of prescription drug misuse. An approach that is communicated with patients as part of a treatment agreement and, whenever possible, standardized across a practice, improves time efficiency and fairness. Prescription drug misuse occurs along a spectrum of risk, from lower risk behaviors (eg, a single episode of a patient taking an extra dose because of severe pain) to higher risk behaviors (eg, regular nonprescribed use). The first clinician response to misuse behaviors should always be discuss it with the patient in a nonjudgmental way and to assess for substance use disorder and overdose risk. Decisions about changes to the treatment plan depend on risk. As an example, a response to a single minor deviation from the patient’s treatment agreement may be to counsel the patient and intensify monitoring; a response to severe or persistent misuse may be to safely taper or discontinue controlled substances and initiate treatment for substance use disorder if present.
        </p>
        <p>
         In most cases of prescription drug misuse, it is appropriate to slowly taper rather than abruptly discontinuing the medication to avoid precipitating a severe withdrawal syndrome [
         <a href="#rid90">
          90,91
         </a>
         ] and other negative consequences.
        </p>
        <p>
         If a patient is suspected of having a substance use disorder, tapering is insufficient and offering or referring for addiction treatment is essential. Many effective treatment options are available [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
         Treatment of substance use disorder is discussed in detail elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/108803.html" rel="external">
          "Opioid use disorder: Treatment overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7803.html" rel="external">
          "Opioid use disorder: Pharmacologic management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99647.html" rel="external">
          "Opioid use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/88407.html" rel="external">
          "Benzodiazepine use disorder", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/106878.html" rel="external">
          "Stimulant use disorder: Treatment overview"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/16750.html" rel="external">
          "Stimulant use disorder: Psychosocial management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/7802.html" rel="external">
          "Cocaine use disorder: Epidemiology, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3633194387">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114308.html" rel="external">
          "Society guideline links: Cannabis use disorder and withdrawal"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/113643.html" rel="external">
          "Society guideline links: Opioid use disorder and withdrawal"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/115010.html" rel="external">
          "Society guideline links: Stimulant use disorder and withdrawal"
         </a>
         and
         <a class="medical medical_society_guidelines" href="/z/d/html/114814.html" rel="external">
          "Society guideline links: Benzodiazepine use disorder and withdrawal"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12924425">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Terminology
         </strong>
         – Prescription drug misuse is defined as use of a prescription medication that is outside of the manner and intent for which it was prescribed; this includes overuse, use to get high, diversion (sharing or selling to others), having multiple prescribers or nonprescribed sources of the medication, and concurrent use of alcohol, illicit substances, or nonprescribed controlled medications. Misuse is a necessary but not sufficient criterion for a substance use disorder. (See
         <a class="local">
          'Prescription drug misuse'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Due to their potential for misuse, addiction, and illicit diversion and sale, opioid analgesics, stimulants, and benzodiazepines and other sedatives/hypnotics are regulated, restricting whether and how they can be prescribed. In the United States, these drugs are referred to as "controlled substances" and subject to Federal regulations  (
         <a class="graphic graphic_table graphicRef66064" href="/z/d/graphic/66064.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Controlled substances'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Epidemiology
         </strong>
         – Misuse of prescription drugs has generally followed trends concurrent with prescribing of medication for therapeutic use. This was particularly true of opioid analgesics prescribed for patients with chronic pain, stimulants prescribed for individuals with attention deficit hyperactivity disorder, and benzodiazepines prescribed for patients with anxiety; misuse increased with greater prescribing for each between 2000 and 2015. (See
         <a class="local">
          'Epidemiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Opioid-related deaths
         </strong>
         – Use of opioid analgesics for pain management increased markedly from the 1990s to the mid-2010s, concurrent with marked increases in associated morbidity and mortality from use and/or misuse of these drugs. While rates of overdose deaths involving prescription opioids have plateaued over the past decade, opioid-related deaths overall have continued to grow, driven by illicit opioids. Higher daily doses of prescribed opioids are associated with a greater risk of overdose for the patient they were prescribed to. (See
         <a class="local">
          'Morbidity and mortality'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention
         </strong>
         – Principal strategies for clinicians to prevent prescription drug misuse and its consequences are optimization of alternative treatments, patient risk assessment, use of a treatment agreement, and limiting dose and early refills. Patient risk assessment should include a history, physical examination, and consideration of the presence of contraindications to prescribing controlled substances (see
         <a class="local">
          'Prevention'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Current untreated substance use disorder
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Poorly controlled psychiatric illness
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Erratic follow-up
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Identification and monitoring
         </strong>
         – Monitoring patients who are prescribed a controlled substance should include regular follow-up, drug testing, and use of prescription monitoring programs or other information sources about patients who receive these medications from multiple prescribers. Monitoring should include documentation of benefits and harms of treatment, including assessment of functional status to assure that function is stable or improving on the current regimen, and evaluation for concerning behaviors that may indicate misuse or a substance use disorder. (See
         <a class="local">
          'Identification and management'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Addressing misuse
         </strong>
         – Prescription drug misuse occurs along a spectrum of risk, from lower risk behaviors (eg, a single episode of a patient taking more than prescribed) to more severe behaviors (eg, undisclosed prescription sources). The clinician's response should be commensurate with the severity and the pattern of the behaviors. Patients suspected of having a substance use disorder should be assessed by an addiction specialist. (See
         <a class="local">
          'Addressing misuse'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1142490615">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Theodore Parran, MD, Bonnie Wilford, MS, and Robert DuPont, MD, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, in NSDUH Series H-44, HHS 2012. Rockville, MD 2012.
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Castle L, Aubert RE, Verbrugge RR, et al. Trends in medication treatment for ADHD. J Atten Disord 2007; 10:335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kuehn BM. Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 2007; 297:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bachhuber MA, Hennessy S, Cunningham CO, Starrels JL. Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013. Am J Public Health 2016; 106:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Von Korff M, Dublin S, Walker RL, et al. The Impact of Opioid Risk Reduction Initiatives on High-Dose Opioid Prescribing for Patients on Chronic Opioid Therapy. J Pain 2016; 17:101.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCabe SE, West BT, Veliz P, et al. Trends in Medical and Nonmedical Use of Prescription Opioids Among US Adolescents: 1976-2015. Pediatrics 2017.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bykov K, He M, Gagne JJ. Trends in Utilization of Prescribed Controlled Substances in US Commercially Insured Adults, 2004-2019. JAMA Intern Med 2020; 180:1006.
          </a>
         </li>
         <li class="breakAll">
          2021 NSDUH Annual National Report. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/report/2021-nsduh-annual-national-report (Accessed on December 18, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fleming MF, Balousek SL, Klessig CL, et al. Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 2007; 8:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ives TJ, Chelminski PR, Hammett-Stabler CA, et al. Predictors of opioid misuse in patients with chronic pain: a prospective cohort study. BMC Health Serv Res 2006; 6:46.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid MC, Engles-Horton LL, Weber MB, et al. Use of opioid medications for chronic noncancer pain syndromes in primary care. J Gen Intern Med 2002; 17:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morasco BJ, Dobscha SK. Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain. Gen Hosp Psychiatry 2008; 30:93.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Banta-Green CJ, Merrill JO, Doyle SR, et al. Measurement of opioid problems among chronic pain patients in a general medical population. Drug Alcohol Depend 2009; 104:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Polatin PB, Kinney RK, Gatchel RJ, et al. Psychiatric illness and chronic low-back pain. The mind and the spine--which goes first? Spine (Phila Pa 1976) 1993; 18:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michna E, Ross EL, Hynes WL, et al. Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history. J Pain Symptom Manage 2004; 28:250.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griesler PC, Hu MC, Wall MM, Kandel DB. Medical Use and Misuse of Prescription Opioids in the US Adult Population: 2016-2017. Am J Public Health 2019; 109:1258.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schepis TS, McCabe SE, Ford JA. Recent trends in prescription drug misuse in the United States by age, race/ethnicity, and sex. Am J Addict 2022; 31:396.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schepis TS, Wastila L, Ammerman B, et al. Prescription Opioid Misuse Motives in US Older Adults. Pain Med 2020; 21:2237.
          </a>
         </li>
         <li class="breakAll">
          https://www.drugabuse.gov/trends-statistics/monitoring-future/monitoring-future-study-trends-in-prevalence-various-drugs (Accessed on May 31, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kelley-Quon LI, Cho J, Strong DR, et al. Association of Nonmedical Prescription Opioid Use With Subsequent Heroin Use Initiation in Adolescents. JAMA Pediatr 2019; 173:e191750.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vowles KE, McEntee ML, Julnes PS, et al. Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis. Pain 2015; 156:569.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Boscarino JA, Rukstalis M, Hoffman SN, et al. Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system. Addiction 2010; 105:1776.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liebschutz JM, Saitz R, Weiss RD, et al. Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain. J Pain 2010; 11:1047.
          </a>
         </li>
         <li class="breakAll">
          Substance Abuse Treatment Admissions by Primary Substance of Abuse,
According to Sex, Age Group, Race, and Ethnicity, 2013. http://wwwdasis.samhsa.gov/webt/quicklink/US13.htm (Accessed on June 02, 2016).
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The TEDS Report: 2001-2011 National Admissions to Substance Abuse Treatment Services. 2013; Rockville, MD.
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. The TEDS Report: A Comparison of Rural and Urban Substance Abuse Treatment Admissions. Rockville, MD July 31, 2012.
         </li>
         <li class="breakAll">
          Quick statistics. Substance Abuse and Mental Health Services Administration. https://www.samhsa.gov/data/quick-statistics-results?qs_type=teds&amp;state=United%20States&amp;year=2019&amp;type=Admissions&amp;view=full (Accessed on December 18, 2022).
         </li>
         <li class="breakAll">
          https://www.cdc.gov/drugoverdose/epidemic/index.html (Accessed on April 14, 2018).
         </li>
         <li class="breakAll">
          Drug Overdose Death Rates. National Institute on Drug Abuse. https://nida.nih.gov/research-topics/trends-statistics/overdose-death-rates (Accessed on December 18, 2022).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kandel DB, Hu MC, Griesler P, Wall M. Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances. Drug Alcohol Depend 2017; 178:501.
          </a>
         </li>
         <li class="breakAll">
          https://www.drugabuse.gov/related-topics/trends-statistics/overdose-death-rates (Accessed on June 02, 2016).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carlson RG, Nahhas RW, Martins SS, Daniulaityte R. Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study. Drug Alcohol Depend 2016; 160:127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Edlund MJ, Steffick D, Hudson T, et al. Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain. Pain 2007; 129:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riva JJ, Noor ST, Wang L, et al. Predictors of Prolonged Opioid Use After Initial Prescription for Acute Musculoskeletal Injuries in Adults : A Systematic Review and Meta-analysis of Observational Studies. Ann Intern Med 2020; 173:721.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griesler PC, Hu MC, Wall MM, Kandel DB. Assessment of Prescription Opioid Medical Use and Misuse Among Parents and Their Adolescent Offspring in the US. JAMA Netw Open 2021; 4:e2031073.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wasan AD, Butler SF, Budman SH, et al. Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 2007; 23:307.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           LaRowe LR, Powers JM, Garey L, et al. Pain-related anxiety, sex, and co-use of alcohol and prescription opioids among adults with chronic low back pain. Drug Alcohol Depend 2020; 214:108171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chabal C, Erjavec MK, Jacobson L, et al. Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors. Clin J Pain 1997; 13:150.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kaye S, Darke S. The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care? Addiction 2012; 107:467.
          </a>
         </li>
         <li class="breakAll">
          SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2015 and 2016. https://www.samhsa.gov/data/sites/default/files/NSDUH-DetTabs-2016/NSDUH-DetTabs-2016.htm#tab1-51B.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wilens TE, Adler LA, Adams J, et al. Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am Acad Child Adolesc Psychiatry 2008; 47:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bogle KE, Smith BH. Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences. Curr Drug Abuse Rev 2009; 2:157.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hedegaard H, Miniño AM, Warner M. Drug Overdose Deaths in the United States, 1999-2018. NCHS Data Brief 2020; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Suen LW, Davy-Mendez T, LeSaint KT, et al. Emergency department visits and trends related to cocaine, psychostimulants, and opioids in the United States, 2008-2018. BMC Emerg Med 2022; 22:19.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spiller HA, Hays HL, Aleguas A Jr. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management. CNS Drugs 2013; 27:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Looby A, De Young KP, Earleywine M. Challenging expectancies to prevent nonmedical prescription stimulant use: a randomized, controlled trial. Drug Alcohol Depend 2013; 132:362.
          </a>
         </li>
         <li class="breakAll">
          Center for Behavioral Health Statistics and Quality. Behavioral health trends in the United States: Results from the 2014 National Survey on Drug Use and Health. SAMHSA; Department of Health and Human Services, Rockville, MD 2015.
         </li>
         <li class="breakAll">
          https://www.samhsa.gov/data/sites/default/files/NSDUH-FFR2-2015/NSDUH-FFR2-2015.htm.
         </li>
         <li class="breakAll">
          Prescription Tranquilizer or Sedative Use Disorder. Key Substance Use and Mental Health Indicators in the United States:
Results from the 2019 National Survey on Drug Use and Health. https://www.samhsa.gov/data/sites/default/files/reports/rpt29393/2019NSDUHFFRPDFWHTML/2019NSDUHFFR090120.htm#sud8 (Accessed on December 18, 2022).
         </li>
         <li class="breakAll">
          Substance Abuse and Mental Health Services Administration. The TEDS Report: Admissions Reporting Benzodiazepine and Narcotic PainReliever Abuse at Treatment Entry. Rockville, MD 2012.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300:2613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park TW, Saitz R, Ganoczy D, et al. Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study. BMJ 2015; 350:h2698.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weisberg DF, Gordon KS, Barry DT, et al. Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients. J Acquir Immune Defic Syndr 2015; 69:223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Liu S, O'Donnell J, Gladden RM, et al. Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines - 38 States and the District of Columbia, 2019-2020. MMWR Morb Mortal Wkly Rep 2021; 70:1136.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Becker WC, Fiellin DA, Desai RA. Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates. Drug Alcohol Depend 2007; 90:280.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chou R, Fanciullo GJ, Fine PG, et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J Pain 2009; 10:113.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowell D, Ragan KR, Jones CM, et al. CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022. MMWR Recomm Rep 2022; 71:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Butler SF, Budman SH, Fernandez K, Jamison RN. Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 2004; 112:65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Compton PA, Wu SM, Schieffer B, et al. Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance. J Pain Symptom Manage 2008; 36:383.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 2005; 6:432.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starrels JL, Becker WC, Alford DP, et al. Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Ann Intern Med 2010; 152:712.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Paulozzi LJ, Kilbourne EM, Shah NG, et al. A history of being prescribed controlled substances and risk of drug overdose death. Pain Med 2012; 13:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescriptions for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdose-related deaths. JAMA 2011; 305:1315.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Demidenko MI, Dobscha SK, Morasco BJ, et al. Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users. Gen Hosp Psychiatry 2017; 47:29.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oliva EM, Bowe T, Manhapra A, et al. Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ 2020; 368:m283.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez HR, Buonora M, Cunningham CO, et al. Opioid Taper Is Associated with Subsequent Termination of Care: a Retrospective Cohort Study. J Gen Intern Med 2020; 35:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Binswanger IA, Glanz JM, Faul M, et al. The Association between Opioid Discontinuation and Heroin Use: A Nested Case-Control Study. Drug Alcohol Depend 2020; 217:108248.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coffin PO, Rowe C, Oman N, et al. Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain. PLoS One 2020; 15:e0232538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mark TL, Parish W. Opioid medication discontinuation and risk of adverse opioid-related health care events. J Subst Abuse Treat 2019; 103:58.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James JR, Scott JM, Klein JW, et al. Mortality After Discontinuation of Primary Care-Based Chronic Opioid Therapy for Pain: a Retrospective Cohort Study. J Gen Intern Med 2019; 34:2749.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glanz JM, Binswanger IA, Shetterly SM, et al. Association Between Opioid Dose Variability and Opioid Overdose Among Adults Prescribed Long-term Opioid Therapy. JAMA Netw Open 2019; 2:e192613.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dowell D, Haegerich TM, Chou R. CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016. JAMA 2016; 315:1624.
          </a>
         </li>
         <li class="breakAll">
          Federation of State Medical Boards. Model Policy on the Use of Opioid Analgesics in the Treatment of Chronic Pain. 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gourlay DL, Heit HA, Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005; 6:107.
          </a>
         </li>
         <li class="breakAll">
          Federation of State Medical Boards. Model policy for the use of controlled substances for the treatment of pain. 2004.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fishbain DA, Cutler RB, Rosomoff HL, Rosomoff RS. Validity of self-reported drug use in chronic pain patients. Clin J Pain 1999; 15:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz NP, Sherburne S, Beach M, et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003; 97:1097.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuckman H, Hazelett S, Powell C, Steer S. A validation of self-reported substance use with biochemical testing among patients presenting to the emergency department seeking treatment for backache, headache, and toothache. Subst Use Misuse 2008; 43:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robinson-Papp J, Elliott K, Simpson DM, et al. Problematic prescription opioid use in an HIV-infected cohort: the importance of universal toxicology testing. J Acquir Immune Defic Syndr 2012; 61:187.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michna E, Jamison RN, Pham LD, et al. Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings. Clin J Pain 2007; 23:173.
          </a>
         </li>
         <li class="breakAll">
          Bronstein K PS, Munitz L, Leider H. Can clinicians accurately predict which patients are misusing their medications?. American Pain Society 30th Annual Scientific Meeting 2011; Austin, TX.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reisfield GM, Bertholf R, Barkin RL, et al. Urine drug test interpretation: what do physicians know? J Opioid Manag 2007; 3:80.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reisfield GM, Webb FJ, Bertholf RL, et al. Family physicians' proficiency in urine drug test interpretation. J Opioid Manag 2007; 3:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Starrels JL, Fox AD, Kunins HV, Cunningham CO. They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain. J Gen Intern Med 2012; 27:1521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           del Portal DA, Healy ME, Satz WA, McNamara RM. Impact of an Opioid Prescribing Guideline in the Acute Care Setting. J Emerg Med 2016; 50:21.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid DBC, Shah KN, Shapiro BH, et al. Mandatory Prescription Limits and Opioid Utilization Following Orthopaedic Surgery. J Bone Joint Surg Am 2019; 101:e43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weiner SG, Baker O, Poon SJ, et al. The Effect of Opioid Prescribing Guidelines on Prescriptions by Emergency Physicians in Ohio. Ann Emerg Med 2017; 70:799.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tannenbaum C, Martin P, Tamblyn R, et al. Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial. JAMA Intern Med 2014; 174:890.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frank JW, Lovejoy TI, Becker WC, et al. Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review. Ann Intern Med 2017; 167:181.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 15236 Version 43.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug Use and Health: Summary of National Findings, in NSDUH Series H-44, HHS 2012. Rockville, MD 2012.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, Arlington, VA 2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17449832" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Trends in medication treatment for ADHD.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17227967" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Opioid prescriptions soar: increase in legitimate use as well as abuse.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26890165" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Increasing Benzodiazepine Prescriptions and Overdose Mortality in the United States, 1996-2013.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26476264" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The Impact of Opioid Risk Reduction Initiatives on High-Dose Opioid Prescribing for Patients on Chronic Opioid Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28320868" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Trends in Medical and Nonmedical Use of Prescription Opioids Among US Adolescents: 1976-2015.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32310250" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Trends in Utilization of Prescribed Controlled Substances in US Commercially Insured Adults, 2004-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32310250" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Trends in Utilization of Prescribed Controlled Substances in US Commercially Insured Adults, 2004-2019.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17499555" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Substance use disorders in a primary care sample receiving daily opioid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16595013" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Predictors of opioid misuse in patients with chronic pain: a prospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11929502" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Use of opioid medications for chronic noncancer pain syndromes in primary care.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18291290" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Prescription medication misuse and substance use disorder in VA primary care patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19473787" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Measurement of opioid problems among chronic pain patients in a general medical population.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8434327" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Psychiatric illness and chronic low-back pain. The mind and the spine--which goes first?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15336337" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Predicting aberrant drug behavior in patients treated for chronic pain: importance of abuse history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31318593" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Medical Use and Misuse of Prescription Opioids in the US Adult Population: 2016-2017.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35441439" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Recent trends in prescription drug misuse in the United States by age, race/ethnicity, and sex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31816076" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Prescription Opioid Misuse Motives in US Older Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31816076" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Prescription Opioid Misuse Motives in US Older Adults.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31282942" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Association of Nonmedical Prescription Opioid Use With Subsequent Heroin Use Initiation in Adolescents.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25785523" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Rates of opioid misuse, abuse, and addiction in chronic pain: a systematic review and data synthesis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20712819" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Risk factors for drug dependence among out-patients on opioid therapy in a large US health-care system.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20338815" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20338815" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20338815" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20338815" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20338815" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20338815" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20338815" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Clinical factors associated with prescription drug use disorder in urban primary care patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28719884" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28719884" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Increases from 2002 to 2015 in prescription opioid overdose deaths in combination with other substances.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26785634" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Predictors of transition to heroin use among initially non-opioid dependent illicit pharmaceutical opioid users: A natural history study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17449178" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Risk factors for clinically recognized opioid abuse and dependence among veterans using opioids for chronic non-cancer pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32805130" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Predictors of Prolonged Opioid Use After Initial Prescription for Acute Musculoskeletal Injuries in Adults : A Systematic Review and Meta-analysis of Observational Studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33410876" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Assessment of Prescription Opioid Medical Use and Misuse Among Parents and Their Adolescent Offspring in the US.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17449991" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32679522" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Pain-related anxiety, sex, and co-use of alcohol and prescription opioids among adults with chronic low back pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9186022" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Prescription opiate abuse in chronic pain patients: clinical criteria, incidence, and predictors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22313101" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22313101" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : The diversion and misuse of pharmaceutical stimulants: what do we know and why should we care?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18174822" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19630746" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Illicit methylphenidate use: a review of prevalence, availability, pharmacology, and consequences.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32487285" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Drug Overdose Deaths in the United States, 1999-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35120449" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Emergency department visits and trends related to cocaine, psychostimulants, and opioids in the United States, 2008-2018.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23757186" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23570818" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Challenging expectancies to prevent nonmedical prescription stimulant use: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23570818" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Challenging expectancies to prevent nonmedical prescription stimulant use: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23570818" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Challenging expectancies to prevent nonmedical prescription stimulant use: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23570818" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Challenging expectancies to prevent nonmedical prescription stimulant use: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23570818" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Challenging expectancies to prevent nonmedical prescription stimulant use: a randomized, controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19066381" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Patterns of abuse among unintentional pharmaceutical overdose fatalities.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26063215" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Benzodiazepine prescribing patterns and deaths from drug overdose among US veterans receiving opioid analgesics: case-cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26009831" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Long-term Prescription of Opioids and/or Benzodiazepines and Mortality Among HIV-Infected and Uninfected Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34437522" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Trends in Nonfatal and Fatal Overdoses Involving Benzodiazepines - 38 States and the District of Columbia, 2019-2020.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17544227" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Non-medical use, abuse and dependence on sedatives and tranquilizers among U.S. adults: psychiatric and socio-demographic correlates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19187889" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36327391" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15494186" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Validation of a screener and opioid assessment measure for patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18508231" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Introduction of a self-report version of the Prescription Drug Use Questionnaire and relationship to medication agreement noncompliance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16336480" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20513829" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Systematic review: treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22026451" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : A history of being prescribed controlled substances and risk of drug overdose death.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20083827" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Opioid prescriptions for chronic pain and overdose: a cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21467284" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Association between opioid prescribing patterns and opioid overdose-related deaths.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28807135" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32131996" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31428983" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Opioid Taper Is Associated with Subsequent Termination of Care: a Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32927194" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : The Association between Opioid Discontinuation and Heroin Use: A Nested Case-Control Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32365132" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Illicit opioid use following changes in opioids prescribed for chronic non-cancer pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31079950" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Opioid medication discontinuation and risk of adverse opioid-related health care events.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31468341" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Mortality After Discontinuation of Primary Care-Based Chronic Opioid Therapy for Pain: a Retrospective Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31002325" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Association Between Opioid Dose Variability and Opioid Overdose Among Adults Prescribed Long-term Opioid Therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26977696" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26977696" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : CDC Guideline for Prescribing Opioids for Chronic Pain--United States, 2016.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15773874" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Universal precautions in pain medicine: a rational approach to the treatment of chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15773874" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Universal precautions in pain medicine: a rational approach to the treatment of chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10524471" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Validity of self-reported drug use in chronic pain patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14500164" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18393078" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : A validation of self-reported substance use with biochemical testing among patients presenting to the emergency department seeking treatment for backache, headache, and toothache.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22820804" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Problematic prescription opioid use in an HIV-infected cohort: the importance of universal toxicology testing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17237667" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17237667" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Urine toxicology screening among chronic pain patients on opioid therapy: frequency and predictability of abnormal findings.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17520987" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Urine drug test interpretation: what do physicians know?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18290585" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Family physicians' proficiency in urine drug test interpretation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22815062" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : They don't know what they don't know: internal medicine residents' knowledge and confidence in urine drug test interpretation for patients with chronic pain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26281819" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Impact of an Opioid Prescribing Guideline in the Acute Care Setting.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31094987" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : Mandatory Prescription Limits and Opioid Utilization Following Orthopaedic Surgery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28549620" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : The Effect of Opioid Prescribing Guidelines on Prescriptions by Emergency Physicians in Ohio.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24733354" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Reduction of inappropriate benzodiazepine prescriptions among older adults through direct patient education: the EMPOWER cluster randomized trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28715848" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Patient Outcomes in Dose Reduction or Discontinuation of Long-Term Opioid Therapy: A Systematic Review.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
